Antiretroviral therapy (ART) recommendations from the International Antiviral Society from December 2022 highlight novel long-acting injectables for PrEP and HIV treatment.

Clarissa Chan, PharmD

Few neurology practices in the United States have embedded pharmacists on their care teams, but a study published December 11, 2022, in the Journal of the American College of Clinical Pharmacy demonstrates how clinical pharmacists could positively affect patients in these settings.

Loren Bonner

Nonprescription products offer preparations to treat a wide range of ears, eyes, nose, and throat (EENT)–related disorders.

The Ninth Judicial District of the Court of Appeals of Ohio recently reversed the dismissal of a plaintiff’s lawsuit against a pharmacy that allegedly failed to provide the plaintiff with prescribed medication.

A patient recently reported that they had been inadvertently taking 2.5 mg of methotrexate—an antineoplastic and immunosuppressant agent—daily for nearly 3 months instead of 10 mg of prasugrel, an antiplatelet agent that had been prescribed.

Four new therapeutic agents are considered in this review, the first in a series of articles on new therapeutic agents marketed in 2022: tirzepatide (Mounjaro–Eli Lilly and Company), daridorexant hydrochloride (Quviviq–Idorsia), tenapanor hydrochloride (Ibsrela–Ardelyx), and vonoprazan fumarate in co-packaging with amoxicillin, and amoxicillin and clarithromycin (Voquezna–Phathom Pharmaceuticals).